Diabetes drug shows promise for quitting smoking without weight gain
NCT ID NCT05610800
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether exenatide, a drug used for diabetes, can help people quit smoking and prevent the weight gain that often happens after quitting. 140 adults who smoked at least 5 cigarettes daily and wanted to quit took part. They received either exenatide or a placebo along with a nicotine patch. The main goals were to see if exenatide improved quit rates and reduced weight gain at 12 weeks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
140 people
The number who actually took part.
- Started
-
Dec 2022
- Finished
-
Mar 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Be willing and able to sign and date an informed consent form, willing to comply with all study procedures, and be available for the duration of the study * Male or female, 18-75 years of age * Have been smoking ≥5 cigarettes per day for at least 1 year and provide positive cotinine test * Desire to quit smoking (defined as "intend to quit within one month") * Have HbA1C levels between 5.7 and 6.4% and/or a body mass index of ≥25 kg/m2 * Have vital signs as follows: resting pulse between 50 and 95 bpm, BP between 90-150 mmHg systolic and 45-95 mmHg diastolic * Have hematology and chemistry laboratory tests that are within reference limits (±10%), with the following exception: pancreatic tests (lipase and amylase) must be within normal limits * Agree (if the subject is female and of child-bearing potential) to use at least one of the following methods of birth control from time of the first administration of the study medication to at least 7 days post the last dose of the study medication, unless the partner is surgically sterile (underwent vasectomy): oral contraceptives, contraceptive sponge, patch, double barrier (diaphragm/spermicidal or condom/spermicidal), intrauterine contraceptive system, etonogestrel implant, medroxyprogesterone acetate contraceptive injection, hormonal vaginal contraceptive ring, or complete abstinence from sexual intercourse. * Women of child-bearing potential must provide negative urine pregnancy tests prior to randomization * Have a medical history and a brief physical examination demonstrating no clinically significant contraindications for study participation, in the judgment of the Study Physician and the PI. Exclusion Criteria: * Psychoactive substance abuse or dependence (excluding nicotine dependence) within the past 3 months (existing diagnosis or as determined by the structured interview) * Currently using chewing tobacco, snuff, snus or electronic cigarettes * Currently enrolled in a smoking cessation program/research study or using pharmacotherapy for smoking cessation (NRT, varenicline, or bupropion) * Currently enrolled in a behavioral weight management plan/research study, or taking medication used for weight management (i.e., orlistat, lorcaserin,\*naltrexone-bupropion, liraglutide, phentermine, benzhetamine, diethylpropion, phendimetrazine), or medication known to impact weight (i.e., corticosteroids) \*Note: Withdrawn from the market in Feb 2020, but some patients may still be taking it * Currently using oral or injectable glucose lowering medications * Urine drug test positive, before randomization, for any of the following substances: benzodiazepines, cocaine, opioids,\*amphetamines, methamphetamine, buprenorphine, barbiturates, 3,4-methylenedioxy-methamphetamine (MDMA), and/or THC. \*Note: If positive for opioids or oxycodone but recent opioid use for acute pain is reported by the study candidate, then the candidate can be included at the discretion of the Primary Investigator and/or Study Physician * Psychotic or bipolar disorder, or mood disorder with psychotic features, or eating disorder (existing diagnosis or as determined by the structured interview) * Moderate to high risk for suicidality (as determined by the structured interview) * Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2) * Type 1 or type 2 diabetes mellitus (previously diagnosed or indicated by HbA1C level of ≥6.5%) * Severe cardiovascular disease (history of myocardial infarction, life-threatening arrhythmia, or worsening angina pectoris) * Severe gastrointestinal disease (i.e., severe gastroparesis) * Previous history of pancreatitis or risk of pancreatitis * Creatinine clearance \<45 mL/min or end stage renal disease (ESRD) * Previous medically adverse reaction to the study medications or nicotine * Women who are currently pregnant, or plan to become pregnant, or lactating, or of childbearing potential and are not using medically accepted forms of contraception. Medically accepted forms of contraception are specified in the inclusion criterion 8. * Current, anticipated, or pending enrollment in another research study over the next 6 months that could potentially affect subject safety and/or the study data/design as determined by the PI and/or Study Physician * Unable to communicate (read, write, and speak) fluently in English * Have any illness or condition which in the opinion of the PI and/or the Study Physician would preclude safe and/or successful completion of the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Smoking cessation are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Michael E. DeBakey VA Medical Center
Houston, Texas, 77030, United States
-
The University of Texas Health Science Center at Houston
Houston, Texas, 77054, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Texts and wearables team up to help latinos quit smoking and get moving
- Can an AI chatbot help cancer patients kick the habit?
- Does the clock matter? scientists randomize when Quit-Smoking chatbots ping you
- Can a WhatsApp message help smokers quit?
- Can a phone app help pregnant women manage weight gain?
- Practice quitting: a new way to help smokers who Aren't ready to stop?